ERBB2 and breast carcinoma: Trastuzumab (Herceptin, Genentech, Inc., South San Francisco, California), an anti-HER2 monoclonal antibody, has been shown to have antitumor activity and a range of mostly low-grade toxic effects in women with metastatic HER2+ breast cancer (12, 13).